We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.
